Treatment of Ovarian Cancer with Liposome-Encapsulated MTP-PE
Author Information
Author(s): S.T.A. Malik, D. Martin, I. Hart, F. Balkwill
Primary Institution: Imperial Cancer Research Fund
Hypothesis
Can intraperitoneal therapy with liposome-encapsulated MTP-PE improve survival in human ovarian cancer xenografts?
Conclusion
Intraperitoneal therapy with liposome-encapsulated MTP-PE significantly prolonged survival in mice with ovarian cancer xenografts.
Supporting Evidence
- 80% of mice with the OS xenograft were cured after treatment.
- The median survival time for the LA xenograft was approximately doubled.
- Combination therapy with GM-CSF and MTP-PE significantly improved survival in some models.
Takeaway
This study tested a new treatment for ovarian cancer using a special medicine that helps mice live longer after getting cancer.
Methodology
Mice with ovarian cancer xenografts were treated with intraperitoneal injections of liposome-encapsulated MTP-PE and/or GM-CSF, and survival was monitored.
Limitations
The study did not optimize the frequency or duration of liposome administration, which may affect results.
Participant Demographics
Mice were 6-12 weeks old, specific pathogen-free, athymic (nu/nu) females of mixed genetic background.
Statistical Information
P-Value
p<0.1 for LA and OS xenografts; p<0.5 for HU xenograft
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website